Calidi (CLDI) Biotherapeutics announced the succession of its Chief Executive Officer, Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi, effective April 22, 2025. Camaisa will continue to serve as a member of the Board.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDI:
- Calidi announces FDA clearance of IND application for CLD-201
- Calidi appoints Guy Travis Clifton as CMO, Consultant, Advisor
- Calidi Biotherapeutics Appoints New Chief Medical Officer
- Calidi Biotherapeutics Reports 2024 Financial Results and Progress
- Calidi reports Q4 EPS Q4 EPS (27c) vs (23c) last year